Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2013

View Archived Issues

Baxter and Coherus Biosciences to develop and commercialize biosimilar products

NIAID to expand funding for development of bicyclolide from Enanta

Kyowa Hakko Kirin and Ultragenyx collaborate on development of KRN-23

Arsanis raises funds for S. aureus program

Diaxonhit and Boehringer Ingelheim enter oncology target agreement

Treatment with CSL-112 leads to rapid removal of cholesterol from atherosclerotic plaques

Clinical comparison and evaluation of treatment dressings in skin graft donors

PV-10 induces systemic tumor-specific immune responses following intralesional injection

Treatment with herbal preparation STW-5-II prevents DSS-induced ulcerative colitis in vivo

Roche presents novel cathepsin S inhibitors

Researchers at Amgen design novel Na(v)1.7 channel blockers

Parkinson's UK provides grant to study PBT-434

SanBio completes enrollment in stem cell SB-623 trial

Addex Therapeutics reports additional preclinical data on dipraglurant

Amgen prepares new agents that inhibit the GCK-GCKR interaction

Navidea awarded additional grant for NAV-4694 beta-amyloid imaging agent

AstraZeneca begins phase III program for olaparib

BNO-1016 shows efficacy in patients with acute viral rhinosinusitis

Rockwell Medical reports findings from CRUISE-2 study of SFP

Syndax grants Eddingpharm Chinese rights to entinostat

Repligen receives milestone from Pfizer for spinal muscular atrophy program

Sanofi and Pozen sign U.S. commercialization agreement for PA-8140 and PA-32540

Neurodyn acquires Memogain from Galantos Pharma

Theravance reports topline results from phase IIb study of TD-4208 for COPD

Vedolizumab BLA for ulcerative colitis receives FDA priority review status

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...